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Abstract
Major depressive disorder (MDD) is a psychiatric disorder, characterized by periods of low mood of more than two weeks,
loss of interest in normally enjoyable activities and behavioral changes. MDD is a complex disorder and does not have a
single genetic cause. In 2009 a genome wide association study (GWAS) was performed on the Dutch GAIN-MDD cohort.
Many of the top signals of this GWAS mapped to a region spanning the gene PCLO, and the non-synonymous coding single
nucleotide polymorphism (SNP) rs2522833 in the PCLO gene became genome wide significant after post-hoc analysis. We
performed resequencing of PCLO, GRM7, and SLC6A4 in 50 control samples from the GAIN-MDD cohort, to detect new
genomic variants. Subsequently, we genotyped these variants in the entire GAIN-MDD cohort and performed association
analysis to investigate if rs2522833 is the causal variant or simply in linkage disequilibrium with a more associated variant.
GRM7 and SLC6A4 are both candidate genes for MDD from literature. We aimed to gather more evidence that rs2522833 is
indeed the causal variant in the GAIN-MDD cohort or to find a previously undetected common variant in either PCLO, GRM7,
or SLC6A4 with a higher association in this cohort. After next generation sequencing and association analysis we excluded
the possibility of an undetected common variant to be more associated. For neither PCLO nor GRM7 we found a more
associated variant. For SLC6A4, we found a new SNP that showed a lower P-value (P = 0.07) than in the GAIN-MDD GWAS
(P = 0.09). However, no evidence for genome-wide significance was found. Although we did not take into account rare
variants, we conclude that our results provide further support for the hypothesis that the non-synonymous coding SNP
rs2522833 in the PCLO gene is indeed likely to be the causal variant in the GAIN-MDD cohort.
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Introduction
Major depressive disorder (MDD) is a psychiatric disorder that
is characterized by persistent dysphoria, loss of interest and
pleasure, changes in appetite and sleep, psychomotor retardation,
feelings of guilt or worthlessness, inability to concentrate and
recurrent thoughts of death or suicide [1]. Environmental
circumstances have proven to influence the aetiology of the
disease. It is more prevalent in women than in men and though
MDD may develop at any age, the mean age of onset is 32 years of
age, with a lifetime prevalence of 16.5%. Worldwide, MDD is one
of the leading causes of disability [2]. The etiology of MDD is still
largely an enigma, but stressful life events (SLEs) are a predictor
for developing a depressive episode [3]. However, from twin
studies it is known that heritability of MDD is approximately 40%
[4].
In 2009, Sullivan et al. performed a GWAS for MDD on the
Dutch GAIN-MDD cohort. Genome-wide significant association
with MDD was not reached, but after post-hoc analysis including
an Australian cohort the non-synonymous coding SNP rs2522833
in the gene PCLO showed nominal significance (P= 6.4E-8) [5].
The Perlegen chip used for this GWAS did not have full genome
tagging capacity nor a gene-centered design, which is why we
previously performed fine-mapping for seven genes that showed
low P-values in the GAIN-MDD GWAS [6]. The increase of SNP
coverage did not lead to the discovery of a more strongly
associated variant. However, when combining the SNPs with the
lowest P-value in PCLO with non-synonymous coding SNP
rs2522833 in one haplotype, the P-value decreased, suggesting a
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e79921
possible undetected variant that is more strongly associated with
MDD in the GAIN-MDD cohort [6]. In addition, in 2009
Bochdanovits et al. showed that either rs2522833 or an unknown
variant that is in high LD with it, is most likely the causal variant in
the GAIN-MDD cohort [7].
The non-synonymous coding SNP rs2522833 is a common
variant with a minor allele frequency (m.a.f.) of 0.4. Since it is a
common variant, we hypothesize that if this SNP is not the causal
variant, the unknown variant that may be causal for the GAIN-
MDD cohort will also be a common variant, as we expect this
variant to be in high LD with rs2522833.
Besides the study of Sullivan et al., In literature there are other
case-control studies replicating the role of PCLO in MDD [8,9]
Moreover, Minelli et al found that the PCLO gene was involved in
personality traits that predispose to depression, showing a role of
PCLO in MDD using endophenotypes [10].
As a follow-up study for the GAIN-MDD GWAS, the aim of
this study is therefore to identify this common causal variant, by
increasing the resolution of genotyping with next generation
sequencing (NGS) followed by association analysis between the
newly identified variants and MDD in the GAIN-MDD cohort.
To accomplish this, we sequenced 50 control samples from the
GAIN-MDD cohort. Controls were used since we expect the
undetected variant to be common and therefore also present in
control samples. In addition, this will allow us to witness this
variant against the background of the normal LD-structure of the
Dutch population. Although we selected controls for sequencing, it
was our aim to find the most associated variant within the cohort.
Bochdanovits et al. in 2009 stated that either rs2522833 would be
causal, or a variant in high LD with it. If homozygotes are selected
for this variant rather than heterozygotes, it increases the
possibility to detect other variants in high LD with the risk allele.
In addition to PCLO, which was selected based on our previous
results, we also sequenced the genes GRM7 and SLC6A4, which
have been studied extensively as functional candidate genes for
MDD in the literature. GRM7 codes for the metabotropic
glutamate receptor 7 and an intronic SNP in this gene showed a
P-value that approximated genome-wide significance in a meta-
analysis of three depression cohorts [11–13]. The SLC6A4 gene
codes for the serotonin transporter gene and plays an important
role in the monoamine hypothesis of depression, according to
which depressive phenotypes are caused by an imbalance in
monoamines like serotonin. This gene has long been the topic of
discussion, as there have been inconsistent results for the
association with MDD of the promoter polymorphism in SLC6A4
combined with SLEs. However, it has been shown that the
polymorphism in the promoter in conjunction with SNPs within
the gene itself and SLEs is more associated with depressive
phenotype than just the promoter and SLEs [14].
Methods and Materials
Samples
The subjects for this study originated from two longitudinal
studies, the Netherlands Study for Depression and Anxiety
(http://www.nesda.nl) [15], designed to be representative of
individuals with depression and/or anxiety disorders, and the
Netherlands Twin Registry (http://www.tweelingenregister.org)
for both of which sample collection and DNA isolation have been
extensively described previously [5,16].
50 control samples from the GAIN-MDD cohort were used for
variant detection. Samples were selected based on their genotype
for rs2522833 in the PCLO gene, with C being the risk allele, and
consisted of 22 males and 28 females. Of the 22 males, 10 were
CC and 12 AA. Of the females, 14 were CC and 14 AA.
For genotyping the detected variants and tag SNPs, we used the
entire GAIN-MDD cohort, consisting of 1738 cases and 1802
controls, of which 1216 were male and 2324 female. All
individuals had an age of 18–65 years and had self-reported
western European ancestry. Ascertainment of cases was from
outpatient specialist mental health facilities and by primary care
screening. Inclusion criteria were a lifetime diagnosis of DSM-IV
MDD as diagnosed by the Composite International Diagnostic
Interview psychiatric interview, age 18–65 years, and self-reported
western European ancestry.
Controls mainly came from the longitudinal cohort of the NTR.
Longitudinal phenotyping includes assessment of depressive
symptoms (via multiple instruments), anxiety, neuroticism and
other personality measures. Inclusion required availability of both
survey data and biological samples, no report of MDD at any
measurement occasion, and low genetic liability for MDD. No
report of MDD was determined by specific queries about
medication use or whether the subject had ever sought treatment
for depression symptoms and/or through the CIDI interview. Low
genetic liability for MDD was determined by the use of a factor
score derived from longitudinal measures of neuroticism, anxiety
and depressive symptoms (mean 0, s.d. 0.7); controls were required
never to have scored highly ($0.65) on this factor score. Finally,
controls and their parents were required to have been born in the
Netherlands or western Europe. Only one control per family was
selected.
Ethical Issues
The NESDA and NTR studies were approved by the Central
Ethics Committee on Research Involving Human Subjects of the
VU University Medical Center, Amsterdam, an Institutional
Review Board certified by the US Office of Human Research
Protections (IRB number IRB-2991 under Federal-wide Assur-
ance-3703; IRB/institute codes, NESDA 03-183; NTR 03-180).
All subjects provided written informed consent. As part of the
GAIN application process, consent forms were specifically re-
reviewed for suitability for the deposit of deidentified phenotype
and genotype data into the controlled-access dbGaP repository
[17]. NESDA and NTR subjects were informed of participation in
GAIN by means of newsletters.
Gene Selection
The genes that were selected for targeted resequencing were
GRM7, PCLO, SLC6A4. PCLO was selected based on the results
from the GAIN-MDD GWAS and our previous fine mapping
efforts, which suggested that either rs2522833 or an undetected
variant in high LD with it would be the causal variant in the
GAIN-MDD cohort. GRM7 and SLC6A4 were selected based on
literature. GRM7 codes for the metabotropic glutamate receptor 7
and was one of the top genes from a meta-analysis for MDD.
SLC6A4 encodes the serotonin transporter, which regulates
serotonin availability in the synaptic cleft. The promoter contains
a length polymorphism that is thought to modulate MDD in
conjunction with SLEs [8–13].
Library Construction
385 K NimbleGen Sequence Capture (Roche NimbleGen, Inc.,
Madison, WI, USA) arrays were custom-designed to capture the
complete genomic locus of the PCLO, GRM7 and SLC6A4 genes,
plus a 10 kb region upstream and downstream of the gene as
defined by the UCSC Genome Browser B37 (http://genome.ucsc.
edu) to capture possible regulatory regions as well. The total area
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consisted of 1,388,868 bp of which 1,217,056 bp was captured on
the array (Table 1). A repeat mask was applied to reduce
interference of genomic regions with a similar sequence.
Sequence capture was performed according to the manufactur-
er’s protocol version 3.0 from December 2008, except for elution
of DNA from the arrays, which was performed according to the
manufacturer’s protocol for elution using sodium hydroxide
version 1.0. After elution, arrays were cleaned using the
NimbleGen Array Reuse Kit according to protocol. As a means
of quality control, qPCR was performed for four control loci and
enrichment was calculated.
At the time that this research was performed, the Roche
Nimblegen and Illumina Solexa (Illumina, Inc., San Diego, CA,
USA) platforms worked with different fragment sizes. In order to
overcome this situation, an intermediate protocol was performed.
Nimblegen fragments were ligated and then fragmented to the size
corresponding to the Illumina protocols. For multiplexing
purposes, index tags were ligated to the samples in order to
identify them after sequencing.
Sequencing
Sequencing was performed using the Illumina Solexa Genome
Analyzer IIx (Illumina Inc., San Diego, CA, USA), by BaseClear
(BaseClear BV, Leiden, The Netherlands). 50 base pair paired-end
reads were generated in a multiplex fashion. Per lane 7 samples
were loaded onto the flow cell, except for one lane that had 8
samples. As a control for the sequencing process, a PhiX DNA
sample was also sequenced in a separate lane.
Assembly and Variant Detection
The assembly of reads as well as variant calling was performed
using CLC Bio Genomics Workbench (CLC Bio, Aarhus,
Denmark). Full chromosome data (Build 37.1, hg19) was
downloaded from NCBI and known variants were annotated
using dbSNP131 from the UCSC Genome Browser. Reads were
mapped back to the entire chromosome, allowing up to one
mismatch and two unaligned nucleotides at the end of the reads or
no mismatches and five unaligned nucleotides at the end of the
reads.
Assembly was performed per sample.
SNP detection was performed for each sample individually.
Minimum coverage was set at 20x and maximum coverage was set
as the theoretical highest average coverage for that particular
sample, by taking the number of reads650 (bp) and dividing that
number by the length of the sequenced region. 35% of reads had
to have an alternative allele in order to be called a heterozygous
variant.
Genotyping Procedure
All genotyping was performed using the Taqman OpenArray
system (Life Technologies, Carlsbad, CA, USA), in accordance
with the protocol of the manufacturer (version: 7/2010). 71 of the
newly identified SNPs with unique sequences were the spotted
onto the arrays. Of the newly detected SNPs with a m.a.f. $10%,
50 bp flanking sequences upstream and downstream were checked
for similarities with other genomic regions using the BLAST tool
[18].
In addition, 185 tag SNPs that were not previously genotyped in
this cohort, were spotted on the arrays with m.a.f. 10% and r2 0.9,
tagging the genes +/210 kb to include possible regulatory regions.
For GRM7 47 new SNPs and 157 tag SNPs were genotyped, for
PCLO 22 new SNPs and 27 tag SNPs, for SLC6A4 2 new SNPs and
1 tag SNP. The tag SNPs were selected by using Tagger software
[19]. Arrays were designed to have 256 assays for 12 samples per
array and were loaded using the OpenArray Accufill robot,
manually loaded into a cassette and then PCR was performed in
an NT cycler. After this, arrays were scanned with the OpenArray
NT Imager. These SNPs were deposited at dbSNP.
The quality of scanned arrays was checked by visually assessing
the location of the array in the scanner (the so-called Spotfind
image) and ROX, VIC and FAM signals using ImageJ, (http://
http://rsbweb.nih.gov/ij/). Genotypes for approximately 200
samples were analyzed simultaneously, using Taqman Genotyper
Software v 1.0.1. This number of 200 samples was set by
optimizing for clear clustering, without getting a bias due to too
few data points. A home-made Perl script [20] was then used to
combine all data and to create a pedigree file.
Association Analysis
After the genotyping procedure, data was merged with
genotyping data from the GAIN-MDD GWAS [5] and for PCLO
with fine-mapping data [6]. We used the genome analysis tool
PLINK to perform an association analysis [21]. We excluded
samples with missing data .25%, SNPs with missing genotypes
.10%, SNPs with m.a.f. ,1% and HWE P-value ,1E-05. A chi-
squared test with one degree of freedom was used to perform the
actual association analysis. A P-value of P= 5E-08 was considered
to be genome-wide significant.
Imputation
For imputation we used Beagle software [22]. 1000 genomes
2010-06 release CEU data was used as a reference [23,24].
We did not use imputation data for the entire chromosome, as
we were only interested in three genes and their regulatory
regions. However, to leave the underlying LD-structure intact, we
used a margin of 100 kb around each gene.
To extract the genes +/2100 kb from the full chromosome data
of the 1000 genomes project, we used a home-made script written
in Python [25]. Imputation was performed per gene with 100
Markov chain iterations, for all samples. All imputation was
performed on the Lisa system cluster (www.sara.nl/systems/lisa).
Gene-based Association
Since PCLO shows several sub-threshold association peaks in an
10E-06 magnitude, we also performed a gene-based association
test and generated a single P-value for this gene rather than P-
values for each SNP, by means of the VEGAS-tool [26]. VEGAS
tests the evidence for association on a per-gene basis by
summarizing the full set of markers and takes LD between
markers into account by using simulation based on the LD
structure of a set of reference individuals. We used our individual
genotype data as a reference set, so that LD would be estimated
specifically for the Dutch population. For each gene one million
simulations were run.




(+/210 kb) Covered on array
% of region
covered
GRM7 900.4 kb 793.3 kb 88.1
PCLO 478.9 kb 376.4 kb 87.8
SLC6A4 59.6 kb 47.4 kb 82.0
doi:10.1371/journal.pone.0079921.t001
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Epistasis Analysis
For each gene we performed an analysis of epistasis. Genes were
classified into gene groups based on cellular function as
determined by previous protein identification and data mining
for synaptic genes and gene function, according to the method of
Ruano et al. [27], in which synaptic genes are subdivided into 17
functional groups of genes on the basis of shared function into a
biological process. We selected genes known to interact with, or be
in the same functional gene group as either GRM7 (G protein-
coupled receptors), or PCLO (proteins involved in regulated
secretion) or SLC6A4 (ion and solute carriers and exchangers).
Using the method of Lips et al. [28], genotypes for the SNPs
existing in these genes were extracted from the GAIN-MDD
GWAS data, after which epistasis analysis was performed with
PLINK [21]. Table 2 depicts how many SNPs were tested for each
gene.
Joint Reanalysis
We performed a joint reanalysis of 92 PCLO SNPs surrounding
rs2522833 and rs2715148. For this analysis, we calculated Z-
scores by performing logistic regression and dividing the slope for
each data point by its standard error, similar to the method used
by Sullivan et al. [5,7] The absolute values of these Z-scores were
then plotted against the square root of the r2 between one of these
92 SNPs with either rs2522833 or rs2715147.
Results
Sequencing
A total of 219 million reads were generated for all samples with
59 million reads mapping back to the region of interest (27%). All
three genes reached an average coverage of at least 25 times and
both GRM7 and SLC6A4 showed coverage of 20 times or higher
for more than 50% of their base pairs. Using only basepairs with a
minimum coverage of 20 times, we detected 4026 SNPs in total, of
which 2658 were known previously in dbSNP131, 406 were found
in the 1000 genomes 2010-06 release CEU data and 961 were
newly discovered (Table 3).
Association Analysis
After variant detection, the GAIN-MDD cohort was genotyped
for high resolution fine mapping using a tagging approach that
included 71 newly discovered SNPs and 185 reported tag SNPs, as
mentioned in methods and materials. The tag SNPs were selected
so that all genes were covered 100% with m.a.f. .10% and
r2 = 0.9, since the newly identified SNPs alone did not provide
100% coverage and we also aimed to recover the underlying LD-
structure of the genes. For GRM7 47 new SNPs and 157 tag SNPs
were genotyped, for PCLO 22 new SNPs and 27 tag SNPs and, for
SLC6A4 2 new SNPs and 1 tag SNP. Several SNPs failed
genotyping as the assays did not cluster very well, as they were
either monomorphic or clusters were too close together to
distinguish between genotypes. This lead to a total genotyping
rate of 96.5% for SNPs. 293 samples (of which 60 cases and 233
controls) failed because of high levels of missing data, leaving a
total of genotyping rate of 97.2% for samples.
After quality control, genotyping data was merged with SNPs
from the GAIN-MDD GWAS and for PCLO also with SNPs from
the fine mapping study that we performed previously [6], to add
up to a total of 479 SNPs in three genes. After performing an
association test with depression status as the dependent variable,
the lowest P-value was found for in PCLO for rs2715147 at
P= 1.5E-06 (OR=0.79). For GRM7 and SLC6A4 the lowest P-
values were P= 6.6E-05 (rs17664833, OR=0.73) and P= 0.07
(SSNP38, OR=1.18), respectively. For GRM7, the P-value was
not lower than the lowest P-value in the GAIN-MDD GWAS. For
SLC6A4, SSNP38 showed a lower P-value than the lowest in the
GAIN-MDD GWAS (P= 0.09).
Imputation
Since several SNPs were excluded from the analysis after quality
control and several samples had missing genotypes, we imputed
these missing genotypes using Beagle with the 1000 genomes CEU
data as a reference panel for all missing genotypes.
We then again performed an association analysis. The lowest P-
value was found for rs2715147 and rs2715148 at 2.3E-06
(OR=0.80), located in the PCLO gene. These two SNPs are in
strong LD with each other (r2 = 0.99) and with rs2522833
(r2 = 0.77); (Figure 1), in our data as well as in the 1000 genomes
data and show a similar m.a.f. in the Dutch population when
compared to the 1000 genomes CEU data. For GRM7 and
SLC6A4 the lowest P-values were 2.61E-05 (rs17664833,
OR=0.71) and 0.08 (SSNP38, OR=1.17), respectively.
These P-values did not provide a better association than the
initial GAIN-MDD GWAS, and are therefore consistent with the
hypothesis that rs2522833 may indeed be the causal variant in this
cohort.
Haplotypes
Using PLINK, we calculated the architecture of haplotype
blocks for each gene, for the genotype data completed with
imputed data. The lowest P-value was found for PCLO at
P= 1.19E-05 (Table 4), showing no genome-wide significance.
However, this block did not contain the SNPs that showed the
lowest single SNP association (rs2715147 and rs2715148). When
assessing the haplotype blocks in Haploview [29], we found that
several SNPs surrounding rs2715147 and rs2715148 had an r2
lower than 0.2 and a single SNP P-value in the range of 0.5-0.1.
Because of this lack of r2 and their high P-values, we created new
haplotype blocks in which these SNPs were not included.
Haplotype-based association analysis was performed again, which
revealed the same block to have the lowest P-value. Nonetheless,
this haplotype block does not show a better association with MDD
than our single SNP association data. Moreover, the haplotype-
based association test does not yield a P-value lower than
rs2522833 in the GAIN-MDD GWAS.
Table 2. The number of SNPs used for the epistasis analysis.
Gene Number of SNPs Number of genes tested against Number of SNPs tested against
GRM7 416 41 1220
PCLO 113 52 1579
SLC6A4 8 29 419
doi:10.1371/journal.pone.0079921.t002
Variant Discovery and Association Analysis
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e79921
Gene-based Association
Using the VEGAS tool, we generated P-values for all three
genes by performing one million simulations. Since the human
genome contains approximately 20,000 genes [30], we corrected
for this number and considered 2.5E-06 (0.05/20,000) to be
significant. Generating a gene-based P-value did not lead to a
lower P-value result, since the lowest P-value was found for PCLO
at P = 1.8E-05.
Epistasis Analysis
For all three genes we performed an epistasis analysis in
PLINK. First we tested all the SNPs that had P-values lower than
10E-05 in the single SNP association analysis. These SNPs yielded
no P-values under 10E-04 in the epistasis analysis. Subsequently
we tested all genotyped SNPs present in GRM7, PCLO and
SLC6A4. The lowest P-value was found for GRM7 rs1516569 in
conjunction with rs9479791 (P= 3.8E-06), located in the intronic
region of OPRM1, which codes for the Opioid Receptor Mu 1. For
PCLO the lowest P-value was found at P= 9.4E-06 for rs17157173
Table 3. Coverage data and newly detected variants over all samples.
Gene GRM7 PCLO SLC6A4
Average Coverage 32.56 26.61 39.26
% bp covered $10x 75.47 61.63 78.98
% bp covered $20x 56.65 39.84 60.85
SNPs detected 2953 954 119
Exonic 8 (1 non-synonymous) 15 (4 non-synonymous) 0
Intronic 2893 885 78
UTR 5 15 9
In dbSNP 1923 659 76
In 1000 genomes project 374 29 3
Newly discovered 655 266 40
% SNPs with m.a.f. ,5% 32.6 28.4 52.1
% SNPs with m.a.f. 5–10% 16.2 14.0 15.1
% SNPs with m.a.f. .10% 51.2 57.6 32.8
doi:10.1371/journal.pone.0079921.t003
Figure 1. LD-plot of the region of interest in PCLO. The SNPs with the lowest P-values, rs2715147 and rs2715148 are in high LD with eachother
and with rs2522833. This supports the hypothesis that either rs2522833 or a SNP in high LD with it is the most likely causal variant in this cohort.
doi:10.1371/journal.pone.0079921.g001
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together with rs16946196 in DLGAP1, which codes for Guanylate
Kinase-Associated Protein (GKAP). The lowest P-value for
SLC6A4 (P = 2.42E-03) was found for rs4251417 with rs233112
in DDAH1, which regulates nitric oxide production. Since after
correction for multiple testing, this epistasis analysis did not lead to
a lower P-value than our single SNP analysis, we conclude that
there is no evidence for an epistatic effect for SNPs of any of these
genes with SNPs from interacting proteins. In addition, in
literature, no effects of interaction between these genes have been
described as yet.
Joint Reanalysis
We then performed a joint reanalysis of 92 SNPs surrounding
rs2522833 and rs2715147. The absolute values of Z-scores were
plotted against the square root of the r2 between one of these 92
SNPs with either rs2522833 or rs2715147. When assuming the
null-hypothesis of no association, one would expect that the slope
of the linear fit would approximate 0, since SNPs in high LD with
a causal variant will reflect the Z-score of this causal variant. When
we assume that rs2522833 is the causal variant, the slope of the
linear fit is 4.00, which increases slightly to 4.15 when assuming
that rs2715147 is the causal variant (Figure 2).
Discussion
For this study our aim was to detect all common variants in the
genes PCLO, GRM7 and SLC6A4 in 50 control samples of the
Dutch GAIN-MDD cohort and then genotype these variants for
the full cohort, in order to test if we could identify a more likely
causal variant than rs2522833 for MDD in this Dutch cohort.
Rs2522833 was the variant with the lowest P-value in the
GAIN-MDD GWAS and the variant with the lowest P-value in
our fine-mapping study (rs2715147) are both common variants in
the Dutch population. Since we expect a causal variant to be in
high LD with these SNPs and these SNPs are common, we would
expect an undetected causal variant also to be common in our
population, allowing control samples to be used. In addition, when
using control samples, one can detect the underlying LD-structure
of the common Dutch population, rather than a putatively skewed
LD-structure in cases.
After genotyping newly identified SNPs and tag SNPs, several
SNPs were excluded by our quality control. In order to acquire
genotypes for all genotyped SNPs, we imputed using Beagle. Both
before and after imputation, we did not find a stronger associated
variant suggesting that rs2522833 may indeed be the causal
variant in the GAIN-MDD GWAS. However, there may be
several other reasons why we did not find a variant with a lower P-
value than rs2522833.
First of all, in the Sullivan GWAS, rs2522833 only became
nominally significant after post-hoc analysis with a cohort that
used a similar method of ascertainment. This could imply that the
sample size is too limited to detect variants with a small effect size.
When looking at GWAS for other complex traits, successes mostly
occur with a substantial larger sample size. This has already led to
the discovery of new loci for example for Parkinson’s disease [31],
multiple sclerosis [32] and breast cancer [33].
Previously, we investigated another cause for the apparent lack
of associated variants: poor SNP coverage [6]. The array that was
used for the GAIN-MDD GWAS, was a relatively early design and
did not fully tag a substantial amount of the genome and was not
designed in a gene-centered manner. This could lead to poor SNP
coverage of certain genes, giving information only about the
variants that have been genotyped for that gene in the GWAS and
those variants that are in strong linkage disequilibrium (LD) with
them. Therefore an associated variant that is not in LD with the
genotyped variant, may go undetected. We tested whether an
increase of SNP coverage may lead to a more associated variant,
and though P-values slightly decreased, no genome-wide signifi-
cance was found.
Thirdly, the phenotype ‘MDD’ may yet be too diffuse to find an
associated variant. One way to solve this predicament is to create
more specialized phenotypes, the so-called ‘endophenotypes’ that
link together genetic factors and biological markers. There are
many physiological steps to go from genetic variants to a
psychiatric disorder, which is why psychiatry hopes to use the
endophenotypes to move closer to the DNA level. A distinct
endophenotype may increase effect size and therefore yield more
significant results. In particular psychiatric disorders may benefit
from endophenotypical descriptions, as their etiology is often
complex and is thought to be a mixture of environmental and
genetic causes [34]. However, this may be a laborious task, since
the complexity of the disorder would lead to many different
endophenotypes to investigate.
Additionally, if a single common variant only has a small effect
size, one would expect epistasis to occur; several variants, which
together cause an increase in risk. However, with the methodology
of a GWAS or a case-control genotyping study, one will not easily
detect all the variants involved in epistasis, exactly because of the
small effect size. An alternative approach to this problem is to
perform gene-based association tests, as genes are the functional
units of the genome. For this, we used the VEGAS method, which
tests the evidence for association on a per-gene basis by
summarizing the full set of markers. It also takes LD between
markers into account by using simulation based on the LD
structure of a set of reference individuals. However, when taking
all SNPs from a certain gene, a weight has to be assigned to each
SNP, for which methods are still under debate. In addition, only
part of the gene –i.e. a single domain- may be involved in the
etiology of the disease. In this case taking the whole gene as a
functional unit may cause a weaker association than when looking
at the association with a specific domain [35], but the means to
perform such tests are still limited. It may also be required for
these tests to expand knowledge about the functions of protein
domains in order to make a logical cut off which SNPs are to be
included in a test. When more is known about the biological
functions of various parts of the protein, one could for instance
Table 4. Haplotypes constructed using PLINK and their respective P-values.
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perform a joint re-analysis of SNPs located in specific domains, to
increase the likelihood to find an association that has biological
implications as well.
Also, we selected the newly detected variants that we genotyped
based on a m.a.f. of more than 10% rather than on physical
position, to increase the probability that the SNPs that we detected
were actual variants instead of artifacts due to sequencing errors or
contamination. It could well be that the variant(s) responsible for
the pathology of MDD have a m.a.f. of less than 10% in our 50
control samples and therefore were not genotyped on the full
GAIN-MDD cohort.
By sequencing 50 control samples we aimed to find a previously
undetected common variant. The region between rs27175147 and
rs2522833 has an average coverage of 25x. However, in the same
region, on average 10% of base pairs had not been covered. This
may explain why an additional variant was not found in this
region. The lack of an associated common variant may also
suggest that the ‘‘common disease, common variant’’ hypothesis
may not hold true for either MDD or for this particular cohort.
Since the beginning of the GWAS era, over 500 associated
common variants have been found for a range of disorders.
However, they usually only explain a small portion of the
heritability and only account for a small increase in risk. An
alternative scenario would encompass multiple rare variants with a
m.a.f. of less than 5% to cause an increase in risk. To detect
variants with an m.a.f. of 1–5%, at least 100 cases would have to
be sequenced. With the per base costs of NGS lowering, it
becomes more feasible to sequence larger groups, enabling the
detection of multiple rare variants which may contribute to
complex disorders [36,37]. In the GAIN-MDD GWAS however,
had rare variants been causal, there would not have been a
marginally significant signal, unless if these rare variants would all
have been recent and in the same haplotype. If these rare variants
would cluster together in the same haplotype, then the variance
explained by them should be so high, that they would have been
expected to appear in linkage studies, which for MDD is not the
case. Mixed models of both rare and common variants are
currently under discussion, as it is indeed likely that complex
disorders are under the influence of variants with various
frequencies [38].
When taking all these factors into account, the fact remains that
in this study as well as in three additional publications an identical
area located in PCLO appears to contain the causal variant [5–7].
The area in which rs2715147, rs2715148 and rs2522833 are
situated shows high r2 values, suggesting that the non-synonymous
coding SNP rs2522833 or a SNP in high LD with it should be
causal for the GAIN-MDD cohort. This SNP was found to be
significant in the GWAS after post-hoc analysis with an Australian
Figure 2. A joint re-analysis of 92 SNPs, in which Z-scores for each SNP are tested against the relative correlation of each SNP with
rs2715147.
doi:10.1371/journal.pone.0079921.g002
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cohort, that used a similar method of ascertainment. The SNP
changes a serine to an alanine in Piccolo’s calcium-binding C2A-
domain. Overexpression of this C2A-domain causes a depression-
like phenotype in mice [39], which makes the PCLO gene still an
interesting candidate gene for MDD.
The selection of the three genes was based on previous results
(PCLO) and on literature (GRM7, SLC6A4). The first gene we
selected, PCLO, is situated on chromosome 7q11.23–q11.30. It
encodes the protein Piccolo, which is located in the presynaptic
active zone. These specialized areas of the presynaptic terminal
have specific cytoskeletal properties to facilitate the preparation
and release of vesicles into the synaptic cleft. In 2008, Leal-Ortiz
et al. [40] showed that Piccolo is not essential for excitatory
synapse formation, but it is a negative regulator of exocytosis,
through modulation of Synapsin dynamics. This was later
supported by Mukherjee et al. [41], who suggested that Piccolo
and its highly homologous brother Bassoon function as tethering
proteins that mediate efficient synaptic vesicle clustering. These
observations make PCLO an interesting functional candidate for
modulating the pathophysiology of MDD, as MDD is suggested to
be caused by an imbalance in monoaminergic neurotransmission
[42]. Besides the GWAS from Sullivan in 2009, a meta-analysis of
three population-based studies also showed a genome-wide
significant P-value for rs2522833, which further underscores a
possible role for PCLO in MDD [9].
The second gene, GRM7, encodes the protein mGluR7. This is
a metabotropic glutamate receptor, which mediates slowly
modulating actions of glutamate on the release of neurotransmit-
ters and the excitability of cells [43]. It is abundant in brain regions
which are known to be critical in anxiolysis and antidepressant
action, such as the amygdala and hippocampus. This suggests that
mGluR7 is involved in the regulatory circuits that influence
anxious and/or depressed behavior. In 2003, Cryan et al showed
that GRM72/2 mice displayed less immobility following various
stress paradigms. However, these anxiolytic/antidepressant results
were still less pronounced than when animals were treated with
anxiolytic drugs like benzodiazepines [11]. Furthermore, Mitsu-
kawa et al., found an increase in glucocorticoid receptors in the
hippocampus of GRM72/2 mice after stress paradigms. This
connects mGluR7 to the hypothalamus-pituitary-adrenal axis
(HPA-axis) which in turn is thought to be a key regulator in the
stress response. In addition, GRM72/2 mice showed lower levels
of the stress hormone corticosterone after stress paradigms than
their GRM7+/+ litter mates [12]. Moreover, in a meta-analysis of
three studies for MDD, one of the strongest association peaks was
observed for GRM7 [43]. In summary, though GRM7 may be an
eligible candidate gene in animal models, in this study we did not
find evidence for a variant that showed a stronger association than
in the GAIN-MDD GWAS.
And finally, SLC6A4 encodes the serotonin transporter, which
plays a pivotal role in the monoamine hypothesis of depression.
The monoamine hypothesis states that depression is caused by the
underactivity/imbalance of monoamines in the brain. The
serotonin transporter regulates the availability of serotonin in the
synaptic cleft by terminating the action of serotonin and recycling
it in a sodium-dependent manner. Consequently, the serotonin
transporter is a target for antidepressant drugs like selective
serotonin reuptake inhibitors (SSRIs) which block the transporter
and thereby increase available serotonin. SLC6A4 has a length
polymorphism in the promoter region, of which the short allele
leads to less transcription of the gene. In 2003, Caspi et al. found a
gene-environment interaction between the short allele and stressful
life events as a predictor for MDD. However, replication efforts
have been inconclusive and a meta-analysis in 2009 did not show
this interaction [13,44]. Although this length polymorphism may
be associated with MDD in interaction with the environment in
the cohort used by Caspi et al. and we found a slightly lower P-
value for this gene, we do not find evidence for genome-wide
association.
In conclusion, while in the 5 kb area between rs2715147 and
rs2522833 in PCLO an average coverage of 25x was reached, we
did not detect an additional common variant. Both in GRM7 and
SLC6A4 previously undetected variants were found as well, but in
neither genes we detected a variant that was more associated with
MDD than rs2522833 in PCLO.
Although we cannot exclude the presence of multiple rare
variants, our results suggest that, in accordance with the findings of
Sullivan et al., non-synonymous coding SNP rs2522833 (or a
variant in high LD with it) in PCLO gene is the causal variant
responsible for the association peak in the GAIN-MDD cohort.
Acknowledgments
Statistical analyses were carried out on the Genetic Cluster Computer
(http://www.geneticcluster.org) which is financially supported by the
Netherlands Scientific Organization (NWO 480-05-003) along with a
supplement from the Dutch Brain Foundation and the VU University
Amsterdam.
We thank Nanne Aben for writing the Python script that was used for
extracting haplotype and SNP data from 1000 genomes data.
We thank Ruben van ’t Slot for assisting us with the adjusted elution
protocol for the sequence capture arrays.
Author Contributions
Conceived and designed the experiments: ECV MRB WJGH PH.
Performed the experiments: ECV IMCB TU PR. Analyzed the data:
ECV ZB. Contributed reagents/materials/analysis tools: PR DIB EJG
BWP JHS. Wrote the paper: ECV.
References
1. American Psychiatric Association Task Force on DSM-IV (1994) Diagnostic and
statistical manual of mental disorders: DSM-IV. Washington, DC: American
Psychiatric Association. xxvii, 886 p.
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005)
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the
National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617–627.
3. Kendler KS, Karkowski LM, Prescott CA (1999) Causal relationship between
stressful life events and the onset of major depression. Am J Psychiatry 156: 837–
841.
4. Kendler KS, Gatz M, Gardner CO, Pedersen NL (2006) A Swedish national
twin study of lifetime major depression. Am J Psychiatry 163: 109–114.
5. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, et al. (2009)
Genome-wide association for major depressive disorder: a possible role for the
presynaptic protein piccolo. Mol Psychiatry 14: 359–375.
6. Verbeek EC, Bakker IM, Bevova MR, Bochdanovits Z, Rizzu P, et al. (2012) A
fine-mapping study of 7 top scoring genes from a GWAS for major depressive
disorder. PLoS One 7: e37384.
7. Bochdanovits Z, Verhage M, Smit AB, de Geus EJ, Posthuma D, et al. (2009)
Joint reanalysis of 29 correlated SNPs supports the role of PCLO/Piccolo as a
causal risk factor for major depressive disorder. Mol Psychiatry 14: 650–652.
8. Aragam N, Wang KS, Pan Y (2011) Genome-wide association analysis of gender
differences in major depressive disorder in the Netherlands NESDA and NTR
population-based samples. J Affect Disord 133: 516–521.
9. Hek K, Mulder CL, Luijendijk HJ, van Duijn CM, Hofman A, et al. (2010) The
PCLO gene and depressive disorders: replication in a population-based study.
Hum Mol Genet 19: 731–734.
10. Minelli A, Scassellati C, Cloninger CR, Tessari E, Bortolomasi M, et al. (2012)
PCLO gene: its role in vulnerability to major depressive disorder. J Affect Disord
139: 250–255.
Variant Discovery and Association Analysis
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e79921
11. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, et al. (2003) Antidepressant
and anxiolytic-like effects in mice lacking the group III metabotropic glutamate
receptor mGluR7. Eur J Neurosci 17: 2409–2417.
12. Mitsukawa K, Mombereau C, Lotscher E, Uzunov DP, van der Putten H, et al.
(2006) Metabotropic glutamate receptor subtype 7 ablation causes dysregulation
of the HPA axis and increases hippocampal BDNF protein levels: implications
for stress-related psychiatric disorders. Neuropsychopharmacology 31: 1112–
1122.
13. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, et al. (2003) Influence of
life stress on depression: moderation by a polymorphism in the 5-HTT gene.
Science 301: 386–389.
14. Lazary J, Lazary A, Gonda X, Benko A, Molnar E, et al. (2008) New evidence
for the association of the serotonin transporter gene (SLC6A4) haplotypes,
threatening life events, and depressive phenotype. Biol Psychiatry 64: 498–504.
15. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, et al. (2008) The
Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives
and methods. Int J Methods Psychiatr Res 17: 121–140.
16. Boomsma DI, Willemsen G, Sullivan PF, Heutink P, Meijer P, et al. (2008)
Genome-wide association of major depression: description of samples for the
GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects.
Eur J Hum Genet 16: 335–342.
17. Mailman MD, Feolo M, Jin Y, Kimura M, Tryka K, et al. (2007) The NCBI
dbGaP database of genotypes and phenotypes. Nat Genet 39: 1181–1186.
18. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local
alignment search tool. J Mol Biol 215: 403–410.
19. de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency
and power in genetic association studies. Nat Genet 37: 1217–1223.
20. Wall L, Christiansen T, Orwant J (2000) Programming Perl. CambridgeMA:
O’Reilly. xxxiii, 1067 p.
21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
22. Browning BL, Browning SR (2009) A unified approach to genotype imputation
and haplotype-phase inference for large data sets of trios and unrelated
individuals. Am J Hum Genet 84: 210–223.
23. Nothnagel M, Ellinghaus D, Schreiber S, Krawczak M, Franke A (2009) A
comprehensive evaluation of SNP genotype imputation. Hum Genet 125: 163–
171.
24. Genomes Project C (2010) A map of human genome variation from population-
scale sequencing. Nature 467: 1061–1073.
25. Sanner MF (1999) Python: A programming language for software integration
and development. Journal of Molecular Graphics & Modelling 17: 57–61.
26. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, et al. (2010) A versatile
gene-based test for genome-wide association studies. Am J Hum Genet 87: 139–
145.
27. Ruano D, Abecasis GR, Glaser B, Lips ES, Cornelisse LN, et al. (2010)
Functional gene group analysis reveals a role of synaptic heterotrimeric G
proteins in cognitive ability. Am J Hum Genet 86: 113–125.
28. Lips ES, Cornelisse LN, Toonen RF, Min JL, Hultman CM, et al. (2012)
Functional gene group analysis identifies synaptic gene groups as risk factor for
schizophrenia. Mol Psychiatry 17: 996–1006.
29. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
30. International Human Genome Sequencing C (2004) Finishing the euchromatic
sequence of the human genome. Nature 431: 931–945.
31. International Parkinson Disease Genomics C, Nalls MA, Plagnol V, Hernandez
DG, Sharma M, et al. (2011) Imputation of sequence variants for identification
of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide
association studies. Lancet 377: 641–649.
32. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C,
Sawcer S, Hellenthal G, Pirinen M, et al. (2011) Genetic risk and a primary role
for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–
219.
33. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, et al. (2009)
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat
Genet 41: 585–590.
34. Kendler KS, Neale MC (2010) Endophenotype: a conceptual analysis. Mol
Psychiatry 15: 789–797.
35. Li MX, Gui HS, Kwan JS, Sham PC (2011) GATES: a rapid and powerful
gene-based association test using extended Simes procedure. Am J Hum Genet
88: 283–293.
36. Cirulli ET, Kasperaviciute D, Attix DK, Need AC, Ge D, et al. (2010) Common
genetic variation and performance on standardized cognitive tests. Eur J Hum
Genet 18: 815–820.
37. Gibson G (2011) Rare and common variants: twenty arguments. Nat Rev Genet
13: 135–145.
38. Wray NR, Purcell SM, Visscher PM (2011) Synthetic associations created by
rare variants do not explain most GWAS results. PLoS Biol 9: e1000579.
39. Furukawa-Hibi Y, Nitta A, Fukumitsu H, Somiya H, Furukawa S, et al. (2010)
Overexpression of piccolo C2A domain induces depression-like behavior in
mice. Neuroreport 21: 1177–1181.
40. Leal-Ortiz S, Waites CL, Terry-Lorenzo R, Zamorano P, Gundelfinger ED, et
al. (2008) Piccolo modulation of Synapsin1a dynamics regulates synaptic vesicle
exocytosis. J Cell Biol 181: 831–846.
41. Mukherjee K, Yang X, Gerber SH, Kwon HB, Ho A, et al. (2010) Piccolo and
bassoon maintain synaptic vesicle clustering without directly participating in
vesicle exocytosis. Proc Natl Acad Sci U S A 107: 6504–6509.
42. Schildkraut JJ (1975) Catecholamines in affective disorders. Psychopharmacol
Bull 11: 35.
43. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, et al. (2011) Novel loci for
major depression identified by genome-wide association study of Sequenced
Treatment Alternatives to Relieve Depression and meta-analysis of three studies.
Mol Psychiatry 16: 202–215.
44. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, et al. (2009) Interaction
between the serotonin transporter gene (5-HTTLPR), stressful life events, and
risk of depression: a meta-analysis. JAMA 301: 2462–2471.
Variant Discovery and Association Analysis
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e79921
